Stocksigma LogoStocksigma Logo

Symbiotec Pharmalab Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million)

■ Revenue: 2,799 (+43.2% YoY | +28.3% QoQ) ■ EBITDA: 915 (+82.0% YoY | +102.5% QoQ) ■ EBITDA Margin (%): 32.7 (+697 bps YoY | +1197 bps QoQ) ■ PAT: 517

Symbiotec Pharmalab Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million)

Symbiotec Pharmalab Ltd · Outcome · 06 Nov 2026, 1:17 am

Symbiotec Pharmalab Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 2,799 (+43.2% YoY | +28.3% QoQ) ■ EBITDA: 915 (+82.0% YoY | +102.5% QoQ) ■ EBITDA Margin (%): 32.7 (+697 bps YoY | +1197 bps QoQ) ■ PAT: 517 (+169.1% YoY | +268.0% QoQ) ■ EPS (INR): 8.20 (+139.1% YoY | +266.1% QoQ)

Original exchange filing (PDF)

More announcements from Symbiotec Pharmalab Ltd

All Symbiotec Pharmalab Ltd announcements